Dr. Crawford on Challenges Facing Active Surveillance

April 12, 2011

E. David Crawford, MD

Video

E. David Crawford, MD from the University of Colorado Health Sciences Center Discusses Challenges Facing Active Surveillance

Related Videos

Joseph G. Jurcic, MD

Kathryn Beckermann, MD, PhD

Sunil Iyer, MD

Erin Crane, MD, MPH

Ibrahim Aldoss, MD

Minoo Battiwalla, MD

Arlene O. Siefker-Radtke, MD

Heinz-Josef Lenz, MD, FACP

Angela Jia, MD, PhD, of University Hospitals

Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute

Related Content

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Stephen J. Freedland, MD

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

prostate cancer

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

18F-PSMA-1007 PET/CT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

Related Content

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Stephen J. Freedland, MD

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

prostate cancer

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

18F-PSMA-1007 PET/CT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

Latest Conference Coverage

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.